BRAF

Chr 7AD

B-Raf proto-oncogene, serine/threonine kinase

Also known as: B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1

BRAF encodes a serine/threonine protein kinase that regulates the MAP kinase/ERK signaling pathway controlling cell division, differentiation, and secretion. Loss-of-function mutations cause autosomal dominant cardiofaciocutaneous syndrome, Noonan syndrome 7, and LEOPARD syndrome 3, which present with overlapping phenotypes including developmental delays, cardiac abnormalities, and distinctive facial features. The gene is extremely intolerant to loss-of-function variation, indicating that haploinsufficiency is the likely pathogenic mechanism in these developmental disorders.

GeneReviewsOMIMResearchSummary from RefSeq, OMIM, UniProt, Mechanism
GOFmechanismADLOEUF 0.217 OMIM phenotypes
VCEP Guidelines: RASopathyReleased
View SpecificationsClinGen Panel
Clinical SummaryBRAF
🧬
Gene-Disease Validity (ClinGen)
Noonan syndrome · ADModerate

Moderate evidence — consider for supplementary testing

4 total gene-disease associations curated

Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 1.00). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
17 unique Pathogenic / Likely Pathogenic· 238 VUS of 500 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available
📖
GeneReview available — BRAF
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Dual constrained — LoF & missense intolerant
LoF Constraint
0.21LOEUF
pLI 1.000
Z-score 5.91
OE 0.10 (0.050.21)
Highly constrained

Highly LoF-intolerant (top ~10% of genes)

Missense Constraint
3.72Z-score
OE missense 0.49 (0.430.55)
203 obs / 416.7 exp
Constrained

Highly missense-constrained (top ~0.1%)

Observed / Expected Ratios
LoF OE0.10 (0.050.21)
00.351.4
Missense OE0.49 (0.430.55)
00.61.4
Synonymous OE1.02
01.21.6
LoF obs/exp: 5 / 50.2Missense obs/exp: 203 / 416.7Syn Z: -0.22
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
definitiveBRAF-related Noonan syndromeGOFAD
definitiveBRAF-related LEOPARD syndromeGOFAD
definitiveBRAF-related cardiofaciocutaneous syndromeGOFAD
DN
0.5279th %ile
GOF
0.6346th %ile
LOF
0.71top 10%

This gene has evidence for multiple mechanisms of pathogenicity (loss-of-function and gain-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to loss-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

LOFprediction above median · LOEUF 0.21
GOF1 literature citation

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Literature Evidence

GOFThe most common activating mutation present within the BRAF oncogene is associated with valine substitution for glutamate at position 600 (V600E) within the BRAF kinase.PMID:29595366

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

ClinVar Variant Classifications

500 submitted variants in ClinVar

Classification Summary

Pathogenic10
Likely Pathogenic7
VUS238
Likely Benign200
Benign4
Conflicting5
10
Pathogenic
7
Likely Pathogenic
238
VUS
200
Likely Benign
4
Benign
5
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
2
8
0
10
Likely Pathogenic
0
7
0
0
7
VUS
16
170
42
10
238
Likely Benign
2
3
59
136
200
Benign
0
0
3
1
4
Conflicting
5
Total18182112147464

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

BRAF · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

NaeviNeurodevelopmental DisorderCongenital Nevus

CongenItal Naevus Cohort for Longitudinal Evaluation

RECRUITING
NCT06828822Phase NANantes University HospitalStarted 2025-07-23
Neurodevelopmental assessmentMeeting with the parentsPatient quality of life assessment
OncologyMEK MutationRAF Gene Mutation

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

RECRUITING
NCT06326411Phase PHASE1Nested Therapeutics, IncStarted 2024-04-09
NST-628
MelanomaNon-Small-Cell Lung CancerThyroid Cancer

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

RECRUITING
NCT05355701Phase PHASE1PfizerStarted 2022-07-05
PF-07799933binimetinibcetuximab
Hairy Cell Leukemia

Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant

RECRUITING
NCT04322383Phase PHASE2National Cancer Institute (NCI)Started 2021-01-07
binimetinib
Histiocytosis

Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis

RECRUITING
NCT04943198Phase PHASE2Anna RaciborskaStarted 2021-04-01
Vemurafenib
Metastatic Colorectal Cancer

Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study

NOT YET RECRUITING
NCT04831528Fudan UniversityStarted 2021-04-10
Cetuximab Ab; Bevacizumab; Vermofenib + cetuximab;Trastuzumab+lapatinib or trastuzumab+pertuzumab; others
Colorectal Cancer Stage IV

Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer

RECRUITING
NCT06509126Phase PHASE3National Cancer Institute, NaplesStarted 2024-06-12
PanitumumabIrinotecan5-fluorouracil
Papillary Thyroid CarcinomaThyroid NeoplasmsRET Proto-Oncogene Mutation

RET-US Study - Ultrasound-Based Prediction of RET Alterations and Lateral-Neck Metastasis in Thyroid Cancer

NOT YET RECRUITING
NCT07042984Fujian Medical UniversityStarted 2025-07-01
AI-Ultrasound RET Prediction
Anaplastic Thyroid CancerThyroid CancerBRAF Gene Mutation

Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

ACTIVE NOT RECRUITING
NCT04238624Phase PHASE2Memorial Sloan Kettering Cancer CenterStarted 2020-01-20
DabrafenibTrametinib
Non-Small Cell Carcinoma of Lung, TNM Stage 4Non-Small Cell Lung CancerEGFR Gene Mutation

Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy

RECRUITING
NCT03042221University of Colorado, DenverStarted 2016-05-10
Stage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7

Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

ACTIVE NOT RECRUITING
NCT02231775Phase PHASE2M.D. Anderson Cancer CenterStarted 2014-10-22
DabrafenibLaboratory Biomarker AnalysisTherapeutic Conventional Surgery
Metastatic Thyroid Gland CarcinomaUnresectable Thyroid Gland Carcinoma

Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery

ACTIVE NOT RECRUITING
NCT01947023Phase PHASE1National Cancer Institute (NCI)Started 2013-09-27
Biopsy ProcedureBiospecimen CollectionComputed Tomography
Clinical Literature
Open Research Assistant →
Full-Text Mentions
NLP-detected gene mentions in article bodies · via PubTator3
PubTator3
Top 5 full-text resultsSearch PubTator3 ↗